MEDIPOST announced that its stem cell drug ‘CARTISTEM^®’ exceeded the 5,000 sales mark (vial) in the domestic market.

Ever since acquiring the approval from the Ministry of Food and Drug Safety for ‘CARTISTEM^®’ in January 2012 and releasing the product in May of the same year, MEDIPOST hit 1,000 sales mark in just 22 months in February 2014.

Hitting 2,000 and 3,000 sales mark with ‘CARTISTEM^®’ took just 13 and 11 months, respectively, and hitting 4,000 sales mark took just 7 and a half months. The sales took off once again and MEDIPOST reached 5,000 sales mark just 6 months after hitting 4,000 sales mark.